产品
编 号：F290924
分子式：C24H31FO4
分子量：402.5
分子式：C24H31FO4
分子量：402.5
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 246246-19-5
产品详情
生物活性：
AL-8810 is a potent and selective antagonist of the PGF 2α receptor (FP receptor). AL-8810 is an activator of MAPK and ERK1/2. The Ki of the FP receptor of mouse 3T3 cells and rat A7r5 cells are 0.2±0.06 μM and 0.4±0.1 μM, respectively. AL-8810 can be used in the study of elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG).
体内研究：
AL-8810 (1 或 10 mg/kg, 静脉注射) 在小鼠中减少缺血性脑损伤和神经毒性。AL-8810 (10 mg/kg, 腹腔注射) 可改善小鼠实验性创伤性脑损伤后的预后。Animal Model:Stroke mouse model
Dosage:1 or 10 mg/kg
Administration:i.v.
Result:Reduced the cortical infarct volume and tape-removal times.
Animal Model:Traumatic brain injury (TBI) model
Dosage:10 mg/kg
Administration:i.p.
Result:Improved neurological deficit scores (NDS) at 24 and 48 hours after controlled cortical impact (CCI).
体外研究：
AL-8810 (0.1, 1, 10 μM, 24 h) 能明显减少 OGD 诱导损伤后的 WT 小鼠神经元细胞死亡。AL-8810 (1, 10 μM, 24 h) 在 HEK 293 和 MG-63 细胞中通过表皮生长因子受体反激活机制促进 ERK1/2 的激活。
AL-8810 is a potent and selective antagonist of the PGF 2α receptor (FP receptor). AL-8810 is an activator of MAPK and ERK1/2. The Ki of the FP receptor of mouse 3T3 cells and rat A7r5 cells are 0.2±0.06 μM and 0.4±0.1 μM, respectively. AL-8810 can be used in the study of elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG).
体内研究：
AL-8810 (1 或 10 mg/kg, 静脉注射) 在小鼠中减少缺血性脑损伤和神经毒性。AL-8810 (10 mg/kg, 腹腔注射) 可改善小鼠实验性创伤性脑损伤后的预后。Animal Model:Stroke mouse model
Dosage:1 or 10 mg/kg
Administration:i.v.
Result:Reduced the cortical infarct volume and tape-removal times.
Animal Model:Traumatic brain injury (TBI) model
Dosage:10 mg/kg
Administration:i.p.
Result:Improved neurological deficit scores (NDS) at 24 and 48 hours after controlled cortical impact (CCI).
体外研究：
AL-8810 (0.1, 1, 10 μM, 24 h) 能明显减少 OGD 诱导损伤后的 WT 小鼠神经元细胞死亡。AL-8810 (1, 10 μM, 24 h) 在 HEK 293 和 MG-63 细胞中通过表皮生长因子受体反激活机制促进 ERK1/2 的激活。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备